中晚期肝癌临床治疗进展

被引：89

作者：

李焱

程朋

机构：

[1] 成都军区总医院肿瘤诊治中心

来源：

临床肝胆病杂志 | 2014年 / 03期

关键词：

肝肿瘤; 放射摄影术,介入性; 药物疗法; 放射疗法; 消融治疗; 综述;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

肝癌的发病隐匿,早期诊断困难,进展较快,临床上仅有不足30%的患者就诊时可获得手术治疗的机会,因此非手术疗法是中晚期肝癌的主要治疗方式。总结了几种主要的非手术治疗方式———血管介入治疗、分子靶向和化疗药物治疗、放疗以及局部消融治疗在肝癌治疗中的地位。认为尽管综合治疗已成为肝癌治疗的共识,但是他们在综合治疗中的地位及次序等仍未形成共识,还需要进行更多的临床研究,从而为中晚期肝癌患者的治疗提供更好的选择。

引用

页码：233 / 236

页数：4

共 16 条

[1]

FOLFOX4方案治疗晚期肝细胞癌的多中心Ⅱ期临床研究 [J].

龚新雷 ;

秦叔逵 ;

王雅杰 ;

邢宝才 ;

吴晴 ;

曹梦苒 ;

华海清 ;

刘秀峰 .

中国新药杂志, 2011, 20 (17) :1673-1677

[2]

Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma[J] Gerhild Becker;Tarik Soezgen;Manfred Olschewski;Joerg Laubenberger;Hubert Erich Blum;Hans-Peter Allgaier; World Journal of Gastroenterology 2005,

[3]

Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines[J] Kenichi Takayasu;Shigeki Arii;Masatoshi Kudo;Takafumi Ichida;Osamu Matsui;Namiki Izumi;Yutaka Matsuyama;Michiie Sakamoto;Osamu Nakashima;Yonson Ku;Norihiro Kokudo;Masatoshi Makuuchi Journal of Hepatology 2011,

[4]

Hemorrhagic Complications of Percutaneous Radiofrequency Ablation for Liver Tumors[J] Eriko Goto;Ryosuke Tateishi;Shuichiro Shiina;Ryota Masuzaki;Kenichiro Enooku;Takahisa Sato;Takamasa Ohki;Yuji Kondo;Tadashi Goto;Haruhiko Yoshida;Masao Omata Journal of Clinical Gastroenterology 2010,

[5]

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma[J] Brian I.Carr;VenkateswarluKondragunta;Shama C.Buch;Robert A.Branch Cancer 2010,

[6]

Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study[J] Johannes Lammer;Katarina Malagari;Thomas Vogl;Frank Pilleul;Alban Denys;Anthony Watkinson;Michael Pitton;Geraldine Sergent;Thomas Pfammatter;Sylvain Terraz;Yves Benhamou;Yves Avajon;Thomas Gruenberger;Maria Pomoni;Herbert Langenberger;Marcus Schuchmann;Jerome Dumortier;Christian Mueller;Patrick Chevallier;Riccardo Lencioni CardioVascular and Inte

[7]

Sunitinib and the benefits of a negative study[J] Alejandro Forner;Josep M Llovet;Jordi Bruix Lancet Oncology 2009,

[8]

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised; double-blind; placebo-controlled trial[J] Ann-Lii Cheng;Yoon-Koo Kang;Zhendong Chen;Chao-Jung Tsao;Shukui Qin;Jun Suk Kim;Rongcheng Luo;Jifeng Feng;Shenglong Ye;Tsai-Sheng Yang;Jianming Xu;Yan Sun;Houjie Liang;Jiwei Liu;Jiejun Wang;Won Young Tak;Hongming Pan;Karin Burock;Jessie Zou;Dimitris Voliotis;Zhongzhen Guan Lancet Oncology 2009,

[9]

Simultaneous Multitarget Irradiation Using Helical Tomotherapy for Advanced Hepatocellular Carcinoma With Multiple Extrahepatic Metastases[J] Jeong Won Jang;Chul Seung Kay;Chan Ran You;Chang Wook Kim;Si Hyun Bae;Jong Young Choi;Seung Kew Yoon;Chi Wha Han;Hyun Suk Jung;Ihl Bong Choi International Journal of Radiation Oncology; Biology; Physics 2009,

[10]

Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Retrospective Study[J] Hui-Hong Liang MD;Min-Shan Chen MD; PhD;Zhen-Wei Peng MD;Yao-Jun Zhang MD;Ya-Qi Zhang MD;Jin-Qing Li MD;Wan Yee Lau MD Annals of Surgical Oncology 2008,

← 1 2 →